Cite
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial
MLA
Robbert de Winter de Winter, et al. Sirolimus-Eluting Stents with Ultrathin Struts versus Everolimus-Eluting Stents for Patients Undergoing Percutaneous Coronary Intervention: Final Three-Year Results of the TALENT Trial. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2d7f32f53a1d6eca047ae9cb9627b738&authtype=sso&custid=ns315887.
APA
Robbert de Winter de Winter, Azfar Zaman, Hironori Hara, Chao Gao, Masafumi Ono, Scot Garg, Pieter Smits Smits, Pim Tonino Tonino, Sjoerd Hofma Hofma, Raul Moreno, Anirban Choudhury, Ivo Petrov, Angel Cequier, Antonio Colombo, Upendra Kaul, Yoshinobu Onuma, & Patrick Serruys Serruys. (2022). Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
Chicago
Robbert de Winter de Winter, Azfar Zaman, Hironori Hara, Chao Gao, Masafumi Ono, Scot Garg, Pieter Smits Smits, et al. 2022. “Sirolimus-Eluting Stents with Ultrathin Struts versus Everolimus-Eluting Stents for Patients Undergoing Percutaneous Coronary Intervention: Final Three-Year Results of the TALENT Trial,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2d7f32f53a1d6eca047ae9cb9627b738&authtype=sso&custid=ns315887.